- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02476591
Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care (PRICE)
Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care: Physician Awareness of ICU Charge Environment: The PRICE Study
Přehled studie
Detailní popis
Ordering providers include resident, fellow and attending physicians, as well as mid level providers such as Nurse Practitioners (NP's) and Physician Assistants (PA's). The investigators have developed a dashboard that displays both daily and cumulative charges related to laboratory, pharmacy, radiology, and other services for all patients admitted to Vanderbilt ICU's. Using this dashboard an ICU ordering provider is able to see not only the total daily charges for the previous 24 hours, but also the sum of all charges for that patient's current ICU admission. In addition, a "snapshot" overview tab is available for each patient that displays a day by day trend of the overall charges of the ICU stay for the patient, top 5 most expensive lab/radiology/pharmacy charges, previous 24 hour charges, and the total ICU number of chest x-ray, Complete Blood Count (CBC), Basic Metabolic Panel (BMP), Electrocardiogram (EKG), and Arterial Blood Gas (ABG) charges to the patient. The ordering provider is able to query the database of the dashboard for information regarding individual laboratory and drug charges, as well as view trajectory of total charges for a given patient. This dashboard allows for unprecedented transparency regarding the cost of care for patients in an ICU. Patients are identified in the dashboard by Medical Record Number (MRN), ICU bed, and initials only so as to protect their identity.
AIM 1: To evaluate the effects of introducing charge transparency to ordering providers via a charge dashboard and associated printed synopsis on average charge per patient per day in the Vanderbilt ICUs.
We intend to study the effect of charge transparency to ordering providers on average charge per patient per day by conducting a prospective, self-controlled by unit, multiple cross-over trial. We will divide the study period into four 12-week blocks with two blocks of "charge transparency" and two blocks of "no transparency." Each unit will be assigned to alternating blocks of "transparency" and "no transparency" during the study with each unit on the same schedule so as to prevent cross contamination.
For months during which access is granted, all ordering providers in the study ICU will be granted access to the ICU charge dashboard following a brief orientation. In addition a password protected, unit specific iPad will be provided to each study unit. The iPad will enable point of care access to the patient specific snapshot information, as well as easily incorporate the dashboard information into clinical care.
AIM 2: To evaluate the effects of utilization of a charge dashboard on ordering patterns of providers and cost containment in the Vanderbilt ICUs.
In addition to studying the effect of charge transparency on patient ICU charges, we also intend to study the effect of charge transparency on resource utilization, namely routine laboratory and radiology tests. As surrogate markers for routine laboratory utilization we will measure average number of Comprehensive Blood Count (CBC) and Basic Metabolic Panel (BMP) tests per patient per day, and as surrogate markers for routine radiology utilization we will use average number of chest x-rays per patient per day.
Typ studie
Zápis (Aktuální)
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- All patients admitted to the Vanderbilt University Medical Center Cardiovascular, Surgical, Burn, Medical and Neuroscience ICUs will be included
Exclusion Criteria:
- There are no exclusion criteria
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Charge transparency
Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
|
Providers caring for patients in the "Charge Transparency" cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs
|
|
Without charge transparency
Providers without access to patient specific charge data
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Average charge per patient per day ($)
Časové okno: 12 week block
|
Sum hospital charges for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average charge per patient per day in the ICU during the study period for each cohort.
|
12 week block
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Average number of Basic Metabolic Panels per patient per day
Časové okno: 12 week blocks
|
Sum total of basic metabolic panels for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of basic metabolic panels per patient per day in the ICU during the study period for each cohort.
|
12 week blocks
|
|
Average number of complete blood counts per patient per day
Časové okno: 12 weeks
|
Sum total of complete blood counts for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of complete blood counts per patient per day in the ICU during the study period for each cohort.
|
12 weeks
|
|
Average number of chest x-rays per patient per day
Časové okno: 12 weeks
|
Sum total of portable chest x-rays for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of chest x-rays per patient per day in the ICU during the study period for each cohort.
|
12 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Adam J Kingeter, MD, Vanderbilt University Medical Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- 150722
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Intenzivní péče
-
Xuzhou Medical UniversityZatím nenabírámeNezinvazivní monitorování CAR-T buněk | BCMA-cílené PET zobrazení | CAR-T buněčná biodistribuce a perzistence | GMP-kompatibilní příprava radiofarmak
-
The Affiliated Hospital of Xuzhou Medical UniversityNáborCLL | SLL | CAR-T buněčná terapieČína
-
University Health Network, TorontoZatím nenabíráme
-
Patrick C. Johnson, MDNábor
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaNáborKomplikace terapie CAR-TItálie
-
Duke UniversityNational Institutes of Health (NIH)NáborTransplantace hematopoetických kmenových buněk | CAR-T buněčná terapieSpojené státy
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHNáborPacientem hlášená výsledná opatření | CAR T-buněčná terapieŠvýcarsko
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesNáborVhodné pro hematopatologii nebo léčba CAR-t buňkamiFrancie
-
Shanghai International Medical CenterNeznámýPokročilý pevný nádor | PD-1 protilátka | CAR-T buňkyČína
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Zatím nenabírámeAlogenní, CAR-T, proteinová sekvestrace, bez genu, upravenoČína